EpiCept To Host Third Quarter 2007 Conference Call and Webcast on November 7,
2007
TARRYTOWN, N.Y., Nov. 3 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq
and OMX Nordic Exchange: EPCT) today announced that it will host a conference
call to discuss third quarter 2007 results and provide a business update on
Wednesday, November 7, 2007 at 8:30 a.m. EST. EpiCept will release results for
the three and nine months ended September 30, 2007 at 12:01 a.m. EST on Monday,
November 5, 2007.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )
To participate in the live call, please dial (888) 802-7346 from the U.S. or
Canada or (973) 582-2785 from international locations (please reference access
code 9431155). The conference call will also be broadcast live on the Internet
and may be accessed at http://www.epicept.com. The webcast will be archived for
90 days.
A telephone replay of the call will be available for seven days by dialing (877)
519-4471 from the U.S. and Canada or (973) 341-3080 from international locations
(please reference reservation number 9431155).
About EpiCept Corporation
EpiCept is focused on unmet needs in the treatment of pain and cancer. EpiCept
has a staged portfolio of pharmaceutical product candidates with several pain
therapies in late-stage clinical trials, and a lead oncology compound for AML
with demonstrated efficacy in a Phase III trial; a marketing authorization
application for this compound has been submitted in Europe. EpiCept is
headquartered in Tarrytown, N.Y. Its research and development team in San Diego
is pursuing a drug discovery program focused on novel approaches to apoptosis.
Forward-Looking Statements
This news release and any oral statements made with respect to the information
contained in this news release, contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include statements which express plans, anticipation,
intent, contingency, goals, targets, future development and are otherwise not
statements of historical fact. These statements are based on EpiCept's current
expectations and are subject to risks and uncertainties that could cause actual
results or developments to be materially different from historical results or
from any future results expressed or implied by such forward-looking statements.
Factors that may cause actual results or developments to differ materially
include: the risk that the proposed public offering will not be consummated,
the risks associated with our need to raise additional financing to continue to
meet our capital needs and our ability to continue as a going concern, the risk
that Ceplene will not receive regulatory approval or marketing authorization in
the EU or that Ceplene, if approved, will not achieve significant commercial
success, the risk that Myriad's development of Azixa(TM) will not be successful,
the risk that Azixa will not receive regulatory approval or achieve significant
commercial success, the risk that we will not receive any significant payments
under our agreement with Myriad, the risk that the development of our other
apoptosis product candidates will not be successful, the risk that our ASAP
technology will not yield any successful product candidates, the risk that
clinical trials for NP-1 or EPC 2407 will not be successful, that NP-1 or EPC
2407 will not receive regulatory approval or achieve significant commercial
success, the risk that our other product candidates that appeared promising in
early research and clinical trials do not demonstrate safety and/or efficacy in
larger-scale or later stage clinical trials, the risk that EpiCept will not
obtain approval to market any of its product candidates, the risks associated
with dependence upon key personnel, the risks associated with reliance on
collaborative partners and others for further clinical trials, development,
manufacturing and commercialization of our product candidates; the cost, delays
and uncertainties associated with our scientific research, product development,
clinical trials and regulatory approval process; our history of operating losses
since our inception; competition; litigation; risks associated with prior
material weaknesses in our internal controls; and risks associated with our
ability to protect our intellectual property. These factors and other material
risks are more fully discussed in EpiCept's periodic reports, including its
reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities
and Exchange Commission. You are urged to carefully review and consider the
disclosures found in EpiCept's filings which are available at www.sec.gov or at
www.epicept.com. You are cautioned not to place undue reliance on any
forward-looking statements, any of which could turn out to be wrong due to
inaccurate assumptions, unknown risks or uncertainties or other risk factors.
*Azixa is a registered trademark of Myriad Genetics, Inc.
EPCT-GEN
SOURCE EpiCept Corporation
-0- 11/03/2007
/CONTACT: Robert W. Cook of EpiCept Corporation, +1-914-606-3500,
rcook@epicept.com; Media: Greg Kelley of Feinstein Kean Healthcare,
+1-617-577-8110, gregory.kelley@fkhealth.com; Investors: Kim Sutton Golodetz,
+1-212-838-3777, kgolodetz@lhai.com, or Bruce Voss, +1-310-691-7100,
bvoss@lhai.com, both of Lippert/Heilshorn & Associates for EpiCept Corporation/
/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com /
/Web site: http://www.epicept.com /
(EPCT)
EpiCept To Host Third Quarter 2007 Conference Call and Webcast on November 7, 2007
| Source: Immune Pharmaceuticals Inc
Attachments
